



COMPANY PROFILE



Noscira is a biopharmaceutical company devoted to the research and development of innovative drugs for the treatment and prevention of diseases of the nervous system.

Since being formed in 2000, the company has focused its activity on Alzheimer's disease, specifically on the search for new approaches which can delay the degenerative course of the disease.

Our strategy combines a unique, highly specialised primary screening platform for marine samples with a strong chemical optimisation effort to convert the identified compounds with biological activity into candidates for toxicological and clinical development. For this Noscira has access to Pharmamar's library for marine samples which includes more than 85,000 species.


Noscira has current staff of 60 of whom 80% are highly qualified employees dedicated to R&D.

At the moment Noscira has the following active lines of research:

- Tau protein phosphorylation inhibitors.
- Amyloidosis inhibitors.
- Neuroprotection.
- Study of the regenerative capacity of olfactory ensheathing glia.
- Other projects in earlier stages of identification, optimisation or characterisation.

Pipeline

Noscira has an active research and development programme aimed at the identification of new compounds for the treatment of diseases of the nervous system.



Partnering & Alliances

Noscira's Business Development Department is open to beginning discussions with potential partners for the purpose of exchanging common interests as well as possible collaboration options on different projects.

For further information about licensing or collaboration opportunities, please contact:

Business Development Department

E-mail: info_bd@noscira.com

web: www.noscira.com

Noscira, S.A.

Avenida de la Industria, 52

Tel.: +34 91 806 11 30

Fax: +34 91 803 46 60

Tres Cantos, Madrid 28760

Spain